<DOC>
	<DOCNO>NCT02929823</DOCNO>
	<brief_summary>The purpose study determine whether SJP-0035 ophthalmic solution effective promote corneal epithelial wound heal condition associate corneal epithelial disorder .</brief_summary>
	<brief_title>Safety Efficacy SJP-0035 Ophthalmic Solution Patients With Moderate Severe Corneal Epithelial Disorders</brief_title>
	<detailed_description>There currently approve product available anywhere worldwide treatment corneal epithelial disorder directly affect epithelium . A Phase 1 study , Study SJP-0035/1-01 , conduct healthy volunteer investigate safety , tolerability , pharmacokinetic profile SJP-0035 ophthalmic solution , determine appropriate dose evaluate patient moderate severe corneal epithelial disorder . A Phase 2a study , Study SJP-0035/2-01 , conduct patient corneal epithelial disorder evaluate efficacy safety SJP-0035 . This Phase 2a study ( Study SJP-0035/2-02 ) conduct evaluate safety efficacy 2 dose SJP-0035 ophthalmic solution patient corneal epithelial disorder . The study evaluate SJP-0035 ophthalmic solution able promote corneal epithelial wound heal patient corneal epithelial disorder use 2 dos SJP-0035 ophthalmic solution ( 0.0002 % 0.001 % ) low use previous Phase 2a study ( Study SJP-0035/2-01 ; 0.005 % ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Is capable understand write informed consent form ( ICF ) , provide sign witness write ICF , agree comply protocol requirement , include require study visit Is male female 18 year age older Has moderate severe corneal epithelial disorder eye Has blur vision cause corneal epithelial disorder eye Screening Randomization Is female childbearing potential negative pregnancy test result Screening Randomization agree use effective contraception throughout study , postmenopausal woman negative pregnancy test result Screening Randomization Has corneal stromal endothelial abnormality include active bacterial viral ocular infection , bullous keratopathy , chemical burn , trauma cornea either eye Screening Randomization Has active chronic allergic , bacterial , viral infection ocular adnexa eye structure either eye Screening Randomization Has intraocular surgery ( include cataract vitreous ) either eye within last 30 day prior first dose study drug Has refractive surgery ( include ocular surface laser surgery ) either eye within last 6 month prior first dose study drug Has use ocular medication ( except mydriatic , stain , topical anesthesia use study assessment ) either eye within 14 day prior first dose study drug , anticipate require medication study . Is contact lens wearer discontinue use eye Screening EOS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>